Serum levels of P-glycoprotein and persistence of disease activity despite treatment in patients with systemic lupus erythematosus
Around 25% of patients with systemic lupus erythematosus (SLE) could be refractory to conventional therapies. P-glycoprotein expression on cell surface has been implied on drug resistance, however, to date, it is unknown if P-gp serum levels are associated with SLE disease activity. Evaluate the ass...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental medicine 2018-02, Vol.18 (1), p.109-117 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 117 |
|---|---|
| container_issue | 1 |
| container_start_page | 109 |
| container_title | Clinical and experimental medicine |
| container_volume | 18 |
| creator | Perez-Guerrero, Edsaul Emilio Gamez-Nava, Jorge Ivan Muñoz-Valle, Jose Francisco Cardona-Muñoz, Ernesto German Bonilla-Lara, David Fajardo-Robledo, Nicte Selene Nava-Zavala, Arnulfo Hernan Garcia-Cobian, Teresa Arcelia Rincón-Sánchez, Ana Rosa Murillo-Vazquez, Jessica Daniela Cardona-Müller, David Vazquez-Villegas, Maria Luisa Totsuka-Sutto, Sylvia Elena Gonzalez-Lopez, Laura |
| description | Around 25% of patients with systemic lupus erythematosus (SLE) could be refractory to conventional therapies. P-glycoprotein expression on cell surface has been implied on drug resistance, however, to date, it is unknown if P-gp serum levels are associated with SLE disease activity. Evaluate the association of serum P-gp levels and SLE with disease activity despite treatment. A cross-sectional study was conducted on 93 female SLE patients, all receiving glucocorticoids at stable doses for the previous 6 months before to baseline. SLE patients were classified into two groups: (a) patients with active disease [SLE disease activity index (SLEDAI) ≥ 3] despite treatment, and (b) patients with inactive disease (SLEDAI |
| doi_str_mv | 10.1007/s10238-017-0459-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1872879462</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1872879462</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-5ed76f1091d34015db220353e6c5a811da11acb74cf1d2da3ebec9169ff35d433</originalsourceid><addsrcrecordid>eNp9kUuLFTEQRhtRnHH0B7iRgBs3rak8ujtLGXzBgIK6DrlJ9UyGfplKj_TWX26aexURdJWCnO9LilNVT4G_BM7bVwRcyK7m0NZcaVPze9U5aAO10aK7f5q7zvCz6hHRLeegO8kfVmeiE0oapc6rH58xrSMb8A4HYnPPPtXXw-bnJc0Z48TcFNiCiSJlnDzuRIiEjpA5n-NdzBsLSEvMyHJCl0ecMivBxeVYRmLfY75htJX8GD0b1mUlhmnLNzi6PNNKj6sHvRsIn5zOi-rr2zdfLt_XVx_ffbh8fVV7xXmuNYa26YEbCFKVTcJBCC61xMZr1wEEB-D8oVW-hyCCk3hAb6AxfS91UFJeVC-OvWW3bytStmMkj8PgJpxXstC1omuNakRBn_-F3s5rmsrvrGiM5iBazf9HgTFKdJqrvQuOlE8zUcLeLimOLm0WuN012qNGWzTaXaPdm5-dmtfDiOF34pe3AogjQOVqusb0x9P_bP0JpwGpyw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1994285042</pqid></control><display><type>article</type><title>Serum levels of P-glycoprotein and persistence of disease activity despite treatment in patients with systemic lupus erythematosus</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Perez-Guerrero, Edsaul Emilio ; Gamez-Nava, Jorge Ivan ; Muñoz-Valle, Jose Francisco ; Cardona-Muñoz, Ernesto German ; Bonilla-Lara, David ; Fajardo-Robledo, Nicte Selene ; Nava-Zavala, Arnulfo Hernan ; Garcia-Cobian, Teresa Arcelia ; Rincón-Sánchez, Ana Rosa ; Murillo-Vazquez, Jessica Daniela ; Cardona-Müller, David ; Vazquez-Villegas, Maria Luisa ; Totsuka-Sutto, Sylvia Elena ; Gonzalez-Lopez, Laura</creator><creatorcontrib>Perez-Guerrero, Edsaul Emilio ; Gamez-Nava, Jorge Ivan ; Muñoz-Valle, Jose Francisco ; Cardona-Muñoz, Ernesto German ; Bonilla-Lara, David ; Fajardo-Robledo, Nicte Selene ; Nava-Zavala, Arnulfo Hernan ; Garcia-Cobian, Teresa Arcelia ; Rincón-Sánchez, Ana Rosa ; Murillo-Vazquez, Jessica Daniela ; Cardona-Müller, David ; Vazquez-Villegas, Maria Luisa ; Totsuka-Sutto, Sylvia Elena ; Gonzalez-Lopez, Laura</creatorcontrib><description>Around 25% of patients with systemic lupus erythematosus (SLE) could be refractory to conventional therapies. P-glycoprotein expression on cell surface has been implied on drug resistance, however, to date, it is unknown if P-gp serum levels are associated with SLE disease activity. Evaluate the association of serum P-gp levels and SLE with disease activity despite treatment. A cross-sectional study was conducted on 93 female SLE patients, all receiving glucocorticoids at stable doses for the previous 6 months before to baseline. SLE patients were classified into two groups: (a) patients with active disease [SLE disease activity index (SLEDAI) ≥ 3] despite treatment, and (b) patients with inactive disease (SLEDAI < 3) after treatment. Forty-three healthy females comprised the control group. Serum P-gp, anti-DNA, and both anti-nucleosome antibody levels were measured using ELISA. Active-SLE patients despite treatment had higher P-gp levels compared with inactive-SLE after treatment (78.02 ng/mL ± 114.11 vs. 33.75 ng/mL ± 41.11;
p
= 0.018) or versus reference group subjects (30.56 ng/mL ± 28.92;
p
= 0.011). P-gp levels correlated with the scores of SLEDAI (
r
= 0.26;
p
= 0.01), Mexican-SLEDAI (MEX-SLEDAI) (
r
= 0.32;
p
= 0.002), SLICC/ACR damage index (
r
= 0.47;
p
< 0.001), and with prednisone doses (
r
= 0.33;
p
= 0.001). In the multivariate model, the high P-gp levels were associated with SLICC/ACR score (
p
= 0.001), and SLEDAI score (
p
= 0.014). Our findings support a relationship between serum P-gp levels and SLE with disease activity despite treatment, but it requires further validation in longitudinal studies.</description><identifier>ISSN: 1591-8890</identifier><identifier>EISSN: 1591-9528</identifier><identifier>DOI: 10.1007/s10238-017-0459-0</identifier><identifier>PMID: 28243944</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Antinuclear - blood ; ATP-Binding Cassette, Sub-Family B, Member 1 - blood ; Cell surface ; Cross-Sectional Studies ; Deoxyribonucleic acid ; DNA ; Drug resistance ; Enzyme-Linked Immunosorbent Assay ; Female ; Glucocorticoids ; Glucocorticoids - administration & dosage ; Glycoproteins ; Health risk assessment ; Hematology ; Humans ; Immunosuppressive Agents - administration & dosage ; Internal Medicine ; Lupus ; Lupus Erythematosus, Systemic - drug therapy ; Lupus Erythematosus, Systemic - pathology ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Article ; P-Glycoprotein ; Patients ; Prednisone ; Serum - chemistry ; Serum levels ; Severity of Illness Index ; Systemic lupus erythematosus ; Volunteers ; Young Adult</subject><ispartof>Clinical and experimental medicine, 2018-02, Vol.18 (1), p.109-117</ispartof><rights>Springer International Publishing Switzerland 2017</rights><rights>Clinical and Experimental Medicine is a copyright of Springer, (2017). All Rights Reserved.</rights><rights>Springer International Publishing Switzerland 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-5ed76f1091d34015db220353e6c5a811da11acb74cf1d2da3ebec9169ff35d433</citedby><cites>FETCH-LOGICAL-c400t-5ed76f1091d34015db220353e6c5a811da11acb74cf1d2da3ebec9169ff35d433</cites><orcidid>0000-0002-6517-6344</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10238-017-0459-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10238-017-0459-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28243944$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perez-Guerrero, Edsaul Emilio</creatorcontrib><creatorcontrib>Gamez-Nava, Jorge Ivan</creatorcontrib><creatorcontrib>Muñoz-Valle, Jose Francisco</creatorcontrib><creatorcontrib>Cardona-Muñoz, Ernesto German</creatorcontrib><creatorcontrib>Bonilla-Lara, David</creatorcontrib><creatorcontrib>Fajardo-Robledo, Nicte Selene</creatorcontrib><creatorcontrib>Nava-Zavala, Arnulfo Hernan</creatorcontrib><creatorcontrib>Garcia-Cobian, Teresa Arcelia</creatorcontrib><creatorcontrib>Rincón-Sánchez, Ana Rosa</creatorcontrib><creatorcontrib>Murillo-Vazquez, Jessica Daniela</creatorcontrib><creatorcontrib>Cardona-Müller, David</creatorcontrib><creatorcontrib>Vazquez-Villegas, Maria Luisa</creatorcontrib><creatorcontrib>Totsuka-Sutto, Sylvia Elena</creatorcontrib><creatorcontrib>Gonzalez-Lopez, Laura</creatorcontrib><title>Serum levels of P-glycoprotein and persistence of disease activity despite treatment in patients with systemic lupus erythematosus</title><title>Clinical and experimental medicine</title><addtitle>Clin Exp Med</addtitle><addtitle>Clin Exp Med</addtitle><description>Around 25% of patients with systemic lupus erythematosus (SLE) could be refractory to conventional therapies. P-glycoprotein expression on cell surface has been implied on drug resistance, however, to date, it is unknown if P-gp serum levels are associated with SLE disease activity. Evaluate the association of serum P-gp levels and SLE with disease activity despite treatment. A cross-sectional study was conducted on 93 female SLE patients, all receiving glucocorticoids at stable doses for the previous 6 months before to baseline. SLE patients were classified into two groups: (a) patients with active disease [SLE disease activity index (SLEDAI) ≥ 3] despite treatment, and (b) patients with inactive disease (SLEDAI < 3) after treatment. Forty-three healthy females comprised the control group. Serum P-gp, anti-DNA, and both anti-nucleosome antibody levels were measured using ELISA. Active-SLE patients despite treatment had higher P-gp levels compared with inactive-SLE after treatment (78.02 ng/mL ± 114.11 vs. 33.75 ng/mL ± 41.11;
p
= 0.018) or versus reference group subjects (30.56 ng/mL ± 28.92;
p
= 0.011). P-gp levels correlated with the scores of SLEDAI (
r
= 0.26;
p
= 0.01), Mexican-SLEDAI (MEX-SLEDAI) (
r
= 0.32;
p
= 0.002), SLICC/ACR damage index (
r
= 0.47;
p
< 0.001), and with prednisone doses (
r
= 0.33;
p
= 0.001). In the multivariate model, the high P-gp levels were associated with SLICC/ACR score (
p
= 0.001), and SLEDAI score (
p
= 0.014). Our findings support a relationship between serum P-gp levels and SLE with disease activity despite treatment, but it requires further validation in longitudinal studies.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Antinuclear - blood</subject><subject>ATP-Binding Cassette, Sub-Family B, Member 1 - blood</subject><subject>Cell surface</subject><subject>Cross-Sectional Studies</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Drug resistance</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Glucocorticoids</subject><subject>Glucocorticoids - administration & dosage</subject><subject>Glycoproteins</subject><subject>Health risk assessment</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Internal Medicine</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - drug therapy</subject><subject>Lupus Erythematosus, Systemic - pathology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>P-Glycoprotein</subject><subject>Patients</subject><subject>Prednisone</subject><subject>Serum - chemistry</subject><subject>Serum levels</subject><subject>Severity of Illness Index</subject><subject>Systemic lupus erythematosus</subject><subject>Volunteers</subject><subject>Young Adult</subject><issn>1591-8890</issn><issn>1591-9528</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kUuLFTEQRhtRnHH0B7iRgBs3rak8ujtLGXzBgIK6DrlJ9UyGfplKj_TWX26aexURdJWCnO9LilNVT4G_BM7bVwRcyK7m0NZcaVPze9U5aAO10aK7f5q7zvCz6hHRLeegO8kfVmeiE0oapc6rH58xrSMb8A4HYnPPPtXXw-bnJc0Z48TcFNiCiSJlnDzuRIiEjpA5n-NdzBsLSEvMyHJCl0ecMivBxeVYRmLfY75htJX8GD0b1mUlhmnLNzi6PNNKj6sHvRsIn5zOi-rr2zdfLt_XVx_ffbh8fVV7xXmuNYa26YEbCFKVTcJBCC61xMZr1wEEB-D8oVW-hyCCk3hAb6AxfS91UFJeVC-OvWW3bytStmMkj8PgJpxXstC1omuNakRBn_-F3s5rmsrvrGiM5iBazf9HgTFKdJqrvQuOlE8zUcLeLimOLm0WuN012qNGWzTaXaPdm5-dmtfDiOF34pe3AogjQOVqusb0x9P_bP0JpwGpyw</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>Perez-Guerrero, Edsaul Emilio</creator><creator>Gamez-Nava, Jorge Ivan</creator><creator>Muñoz-Valle, Jose Francisco</creator><creator>Cardona-Muñoz, Ernesto German</creator><creator>Bonilla-Lara, David</creator><creator>Fajardo-Robledo, Nicte Selene</creator><creator>Nava-Zavala, Arnulfo Hernan</creator><creator>Garcia-Cobian, Teresa Arcelia</creator><creator>Rincón-Sánchez, Ana Rosa</creator><creator>Murillo-Vazquez, Jessica Daniela</creator><creator>Cardona-Müller, David</creator><creator>Vazquez-Villegas, Maria Luisa</creator><creator>Totsuka-Sutto, Sylvia Elena</creator><creator>Gonzalez-Lopez, Laura</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6517-6344</orcidid></search><sort><creationdate>20180201</creationdate><title>Serum levels of P-glycoprotein and persistence of disease activity despite treatment in patients with systemic lupus erythematosus</title><author>Perez-Guerrero, Edsaul Emilio ; Gamez-Nava, Jorge Ivan ; Muñoz-Valle, Jose Francisco ; Cardona-Muñoz, Ernesto German ; Bonilla-Lara, David ; Fajardo-Robledo, Nicte Selene ; Nava-Zavala, Arnulfo Hernan ; Garcia-Cobian, Teresa Arcelia ; Rincón-Sánchez, Ana Rosa ; Murillo-Vazquez, Jessica Daniela ; Cardona-Müller, David ; Vazquez-Villegas, Maria Luisa ; Totsuka-Sutto, Sylvia Elena ; Gonzalez-Lopez, Laura</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-5ed76f1091d34015db220353e6c5a811da11acb74cf1d2da3ebec9169ff35d433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Antinuclear - blood</topic><topic>ATP-Binding Cassette, Sub-Family B, Member 1 - blood</topic><topic>Cell surface</topic><topic>Cross-Sectional Studies</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Drug resistance</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Glucocorticoids</topic><topic>Glucocorticoids - administration & dosage</topic><topic>Glycoproteins</topic><topic>Health risk assessment</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Internal Medicine</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - drug therapy</topic><topic>Lupus Erythematosus, Systemic - pathology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>P-Glycoprotein</topic><topic>Patients</topic><topic>Prednisone</topic><topic>Serum - chemistry</topic><topic>Serum levels</topic><topic>Severity of Illness Index</topic><topic>Systemic lupus erythematosus</topic><topic>Volunteers</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perez-Guerrero, Edsaul Emilio</creatorcontrib><creatorcontrib>Gamez-Nava, Jorge Ivan</creatorcontrib><creatorcontrib>Muñoz-Valle, Jose Francisco</creatorcontrib><creatorcontrib>Cardona-Muñoz, Ernesto German</creatorcontrib><creatorcontrib>Bonilla-Lara, David</creatorcontrib><creatorcontrib>Fajardo-Robledo, Nicte Selene</creatorcontrib><creatorcontrib>Nava-Zavala, Arnulfo Hernan</creatorcontrib><creatorcontrib>Garcia-Cobian, Teresa Arcelia</creatorcontrib><creatorcontrib>Rincón-Sánchez, Ana Rosa</creatorcontrib><creatorcontrib>Murillo-Vazquez, Jessica Daniela</creatorcontrib><creatorcontrib>Cardona-Müller, David</creatorcontrib><creatorcontrib>Vazquez-Villegas, Maria Luisa</creatorcontrib><creatorcontrib>Totsuka-Sutto, Sylvia Elena</creatorcontrib><creatorcontrib>Gonzalez-Lopez, Laura</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perez-Guerrero, Edsaul Emilio</au><au>Gamez-Nava, Jorge Ivan</au><au>Muñoz-Valle, Jose Francisco</au><au>Cardona-Muñoz, Ernesto German</au><au>Bonilla-Lara, David</au><au>Fajardo-Robledo, Nicte Selene</au><au>Nava-Zavala, Arnulfo Hernan</au><au>Garcia-Cobian, Teresa Arcelia</au><au>Rincón-Sánchez, Ana Rosa</au><au>Murillo-Vazquez, Jessica Daniela</au><au>Cardona-Müller, David</au><au>Vazquez-Villegas, Maria Luisa</au><au>Totsuka-Sutto, Sylvia Elena</au><au>Gonzalez-Lopez, Laura</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum levels of P-glycoprotein and persistence of disease activity despite treatment in patients with systemic lupus erythematosus</atitle><jtitle>Clinical and experimental medicine</jtitle><stitle>Clin Exp Med</stitle><addtitle>Clin Exp Med</addtitle><date>2018-02-01</date><risdate>2018</risdate><volume>18</volume><issue>1</issue><spage>109</spage><epage>117</epage><pages>109-117</pages><issn>1591-8890</issn><eissn>1591-9528</eissn><abstract>Around 25% of patients with systemic lupus erythematosus (SLE) could be refractory to conventional therapies. P-glycoprotein expression on cell surface has been implied on drug resistance, however, to date, it is unknown if P-gp serum levels are associated with SLE disease activity. Evaluate the association of serum P-gp levels and SLE with disease activity despite treatment. A cross-sectional study was conducted on 93 female SLE patients, all receiving glucocorticoids at stable doses for the previous 6 months before to baseline. SLE patients were classified into two groups: (a) patients with active disease [SLE disease activity index (SLEDAI) ≥ 3] despite treatment, and (b) patients with inactive disease (SLEDAI < 3) after treatment. Forty-three healthy females comprised the control group. Serum P-gp, anti-DNA, and both anti-nucleosome antibody levels were measured using ELISA. Active-SLE patients despite treatment had higher P-gp levels compared with inactive-SLE after treatment (78.02 ng/mL ± 114.11 vs. 33.75 ng/mL ± 41.11;
p
= 0.018) or versus reference group subjects (30.56 ng/mL ± 28.92;
p
= 0.011). P-gp levels correlated with the scores of SLEDAI (
r
= 0.26;
p
= 0.01), Mexican-SLEDAI (MEX-SLEDAI) (
r
= 0.32;
p
= 0.002), SLICC/ACR damage index (
r
= 0.47;
p
< 0.001), and with prednisone doses (
r
= 0.33;
p
= 0.001). In the multivariate model, the high P-gp levels were associated with SLICC/ACR score (
p
= 0.001), and SLEDAI score (
p
= 0.014). Our findings support a relationship between serum P-gp levels and SLE with disease activity despite treatment, but it requires further validation in longitudinal studies.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>28243944</pmid><doi>10.1007/s10238-017-0459-0</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6517-6344</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1591-8890 |
| ispartof | Clinical and experimental medicine, 2018-02, Vol.18 (1), p.109-117 |
| issn | 1591-8890 1591-9528 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1872879462 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adolescent Adult Aged Aged, 80 and over Antibodies, Antinuclear - blood ATP-Binding Cassette, Sub-Family B, Member 1 - blood Cell surface Cross-Sectional Studies Deoxyribonucleic acid DNA Drug resistance Enzyme-Linked Immunosorbent Assay Female Glucocorticoids Glucocorticoids - administration & dosage Glycoproteins Health risk assessment Hematology Humans Immunosuppressive Agents - administration & dosage Internal Medicine Lupus Lupus Erythematosus, Systemic - drug therapy Lupus Erythematosus, Systemic - pathology Medicine Medicine & Public Health Middle Aged Oncology Original Article P-Glycoprotein Patients Prednisone Serum - chemistry Serum levels Severity of Illness Index Systemic lupus erythematosus Volunteers Young Adult |
| title | Serum levels of P-glycoprotein and persistence of disease activity despite treatment in patients with systemic lupus erythematosus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T06%3A24%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20levels%20of%20P-glycoprotein%20and%20persistence%20of%20disease%20activity%20despite%20treatment%20in%20patients%20with%20systemic%20lupus%20erythematosus&rft.jtitle=Clinical%20and%20experimental%20medicine&rft.au=Perez-Guerrero,%20Edsaul%20Emilio&rft.date=2018-02-01&rft.volume=18&rft.issue=1&rft.spage=109&rft.epage=117&rft.pages=109-117&rft.issn=1591-8890&rft.eissn=1591-9528&rft_id=info:doi/10.1007/s10238-017-0459-0&rft_dat=%3Cproquest_cross%3E1872879462%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1994285042&rft_id=info:pmid/28243944&rfr_iscdi=true |